J. Moon, Jong Ho Park, Ji Heun Jeong, N. Sung, Y. Jeong, K. Song, J. Ahn, N. Lee, Seung-Yun Han
{"title":"Metformin-loaded Citric Acid Cross-linked Agarose Films in the Prevention of Postoperative Abdominal Adhesion","authors":"J. Moon, Jong Ho Park, Ji Heun Jeong, N. Sung, Y. Jeong, K. Song, J. Ahn, N. Lee, Seung-Yun Han","doi":"10.11637/aba.2019.32.4.129","DOIUrl":null,"url":null,"abstract":"Postoperative abdominal adhesion (PAA) causes significant long-term postoperative morbidity. Although numerous physical anti-adhesion barriers (AAB) are used as therapeutical interventions, none of them has achieved sustained success. As a potential strategy to overcome the limitations, drug-eluting AAB have attracted scientific attention. Here, we produced agar films (AF) chemically cross-linked with different concentrations of citric acid (CA) and we measured the physicochemical properties such as crosslinking strength, swelling ratio, hydrophilicity, and biodegradability of the yielded CA-AFs. Next, Metformin (MET), an antidiabetic drug with anti-proliferative and anti-inflammatory properties, was loaded in the CA-AFs yielding the MET-loaded CA-AF (MET@CA-AF) and the time-dependent MET release was monitored. Based on their physicochemical properties, MET@CA-AF containing 20% CA appeared a promising AAB candidate and was further used in an in vivo study. Mouse models of PAA were established with cecum abrasion and the MET@CAAF and CA-AF were applied between the injured interfaces. At postoperative day 14, the therapeutic efficacies were analyzed by using clinical adhesion scoring and quantification of collagen-I and fibroblasts in adhesion interfaces. The results showed that applications of MET@CA-AF or CA-AF for 14 days significantly attenuated the clinical adhesion score and thickness of adhesion interface. Furthermore, when compared with the group with operation, the groups with MET@CA-AF or CA-AF exhibited the significant attenuation in PAA-associated myofibroblast activation in adhesion interface. Importantly, these attenuations were significantly more intensified in the group with MET@CA-AF than in the group with CA-AF. Based on our data, we anticipate that MET@CAAF, a novel synthesized drug-eluting AAB, can protect against PAA by exerting the dual role of physical barrier and MET-based pharmaceutic.","PeriodicalId":356245,"journal":{"name":"Anatomy & Biological Anthropology","volume":"74 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anatomy & Biological Anthropology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.11637/aba.2019.32.4.129","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Postoperative abdominal adhesion (PAA) causes significant long-term postoperative morbidity. Although numerous physical anti-adhesion barriers (AAB) are used as therapeutical interventions, none of them has achieved sustained success. As a potential strategy to overcome the limitations, drug-eluting AAB have attracted scientific attention. Here, we produced agar films (AF) chemically cross-linked with different concentrations of citric acid (CA) and we measured the physicochemical properties such as crosslinking strength, swelling ratio, hydrophilicity, and biodegradability of the yielded CA-AFs. Next, Metformin (MET), an antidiabetic drug with anti-proliferative and anti-inflammatory properties, was loaded in the CA-AFs yielding the MET-loaded CA-AF (MET@CA-AF) and the time-dependent MET release was monitored. Based on their physicochemical properties, MET@CA-AF containing 20% CA appeared a promising AAB candidate and was further used in an in vivo study. Mouse models of PAA were established with cecum abrasion and the MET@CAAF and CA-AF were applied between the injured interfaces. At postoperative day 14, the therapeutic efficacies were analyzed by using clinical adhesion scoring and quantification of collagen-I and fibroblasts in adhesion interfaces. The results showed that applications of MET@CA-AF or CA-AF for 14 days significantly attenuated the clinical adhesion score and thickness of adhesion interface. Furthermore, when compared with the group with operation, the groups with MET@CA-AF or CA-AF exhibited the significant attenuation in PAA-associated myofibroblast activation in adhesion interface. Importantly, these attenuations were significantly more intensified in the group with MET@CA-AF than in the group with CA-AF. Based on our data, we anticipate that MET@CAAF, a novel synthesized drug-eluting AAB, can protect against PAA by exerting the dual role of physical barrier and MET-based pharmaceutic.